ALKEM Alkem Lab Q4 FY25 results (Jan–Mar 2025) and concall
Alkem Laboratories delivered a strong Q4 and FY25, driven by robust India sales and significant EBITDA margin expansion. Strategic investments in biosimilar CDMO and MedTech are progressing, though they are expected to incur initial operating losses in FY26. The company provided clear guidance on FY26 margins, R&D, and tax rates, while acknowledging challenges in Q4 gross margins and the domestic market due to NLEM.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|
| Revenue | 3,415 | 3,374 | 3,144 |
| EBITDA | 753 | 759 | 391 |
| Net profit | 702 | 641 | 322 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
